{
  "source": "PA-Med-Nec-Bimzelx.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2334-5\nProgram Prior Authorization/Medical Necessity\nMedication Bimzelx® (bimekizumab-bkzx)\nP&T Approval Date 4/2024, 6/2024, 10/2024, 1/2025, 4/2025\nEffective Date 6/1/2025\n1. Background:\nBimzelx (bimekizumab-bkzx) is a humanized interleukin-17A and F antagonist indicated for\nthe treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic\ntherapy or phototherapy, adults with active psoriatic arthritis, adults with active non-\nradiographic axial spondyloarthritis with objective signs of inflammation adults with active\nankylosing spondylitis, and adults with moderate to severe hidradenitis suppurativa.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis (PsO)\n1. Initial Authorization\na. Bimzelx will be approved based on the following criterion:\n(1) Diagnosis of moderate to severe plaque psoriasis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement,\npalmoplantar, facial, genital involvement, or severe scalp psoriasis\n-AND-\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\n• Corticosteroids (e.g., betamethasone, clobetasol, desonide)\n• Vitamin D analogs (e.g., calcitriol, calcipotriene)\n• Tazarotene\n• Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\n• Anthralin\n• Coal tar\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\niii. History of failure to a 3 month trial of methotrexate at the maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (document drug, date, and duration\nof therapy",
    "eated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (document drug, date, and duration\nof therapy) [e.g., Enbrel (etanercept), Cimzia (certolizumab), adalimumab,\nOrencia (abatacept), ustekinumab, Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq\n(brodalumab), Ilumya (tildrakizumab), Otezla (apremilast)]\n-AND-\n(3) One of the following:\n(a) History of failure, contraindication, or intolerance to two of the\nfollowing (document drug, date, and duration of trial):\ni. One of the preferred adalimumab productsc\nii. Cimzia (certolizumab)\niii. Cosentyx (secukinumab)\niv. Enbrel (etanercept)\nv. Skyrizi (risankizumab)\nvi. Sotyktu (deucravacitinib)\nvii. One of the preferred ustekinumab productsc\nviii. Tremfya (guselkumab)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Bimzelx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a UCB sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a\nfree supply of medication) as a means to establish as a current user of\nBimzelx*\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(4) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n-AND-\n(5) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufactu",
    "itinib), Otezla\n(apremilast)]\n-AND-\n(5) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a UCB sponsored program shall be required to meet initial\nauthorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,\nSkyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),\nTaltz (ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Bimzelx will be approved based on the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n3\n(a) History of failure to a 3 month trial of methotrexate at maximally indicated\ndose, unless contraindicated or clinically significant adverse effects are\nexperienced (document date and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of psoriatic arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), Cosentyx (secukinumab),\nadalimumab, Simponi (golimumab), ustekinumab, Tremfya (guselkumab),\nXeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi\n(risankizumab), Rinvoq (upadacitinib), Enbrel",
    "Cosentyx (secukinumab),\nadalimumab, Simponi (golimumab), ustekinumab, Tremfya (guselkumab),\nXeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi\n(risankizumab), Rinvoq (upadacitinib), Enbrel (etanercept)]\n-AND-\n(3) One of the following:\n(a) History of failure, contraindication, or intolerance to two of the following\npreferred products (document drug, date, and duration of trial):\ni. One of the preferred adalimumab productsc\nii. Cimzia (certolizumab)\niii. Cosentyx (secukinumab)\niv. Enbrel (etanercept)\nv. Rinvoq (upadacitinib)\nvi. Simponi (golimumab)\nvii. Skyrizi (risankizumab)\nviii. One of the preferred ustekinumab productsc\nix. Tremfya (guselkumab)\nx. Xeljanz/Xeljanz XR (tofacitinib)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Bimzelx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a UCB sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a\nfree supply of medication) as a means to establish as a current user of\nBimzelx*\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n4\n(4) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi\n(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\n-AND-\n(5) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a UCB sponsored program shall be required to meet initial\nauthorization criteria as if patient w",
    " of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a UCB sponsored program shall be required to meet initial\nauthorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),\nSimponi (golimumab), Orencia (abatacept), ustekinumab, Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nC. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Bimzelx will be approved based on the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n-AND-\n(2) One of the following:\n© 2025 UnitedHealthcare Services, Inc.\n5\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at\nmaximally indicated doses, each used for at least 4 weeks, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trials)\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator\nFDA-approved for the treatment of ankylosing spondylitis as documented\nby claims history or submission of medical records (Document drug,\ndate, and duration of therapy) [e.g., adalimumab, Simponi (golimumab),\nRinvoq (upadacitinib), Xeljanz/Xeljanz XR (tofacitinib), Enbrel\n(etanercept)].\n-AND-\n(3) One of the following:\n(a) History of failure, contraindication, or intolerance to two of the following\npreferred products (document drug, date, and duration of trial):\ni. One of the preferred adalimumab productsc\nii. Cimzia (certolizumab)\niii. Cosentyx (secukinumab)\niv. Enbrel (etanercep",
    " the following\npreferred products (document drug, date, and duration of trial):\ni. One of the preferred adalimumab productsc\nii. Cimzia (certolizumab)\niii. Cosentyx (secukinumab)\niv. Enbrel (etanercept)\nv. Rinvoq (upadacitinib)\nvi. Simponi (golimumab)\nvii. Xeljanz/Xeljanz XR (tofacitinib)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Bimzelx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a UCB sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a\nfree supply of medication) as a means to establish as a current user of\nBimzelx*\n-AND-\n(4) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Cosentyx\n© 2025 UnitedHealthcare Services, Inc.\n6\n(secukinumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(5) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a UCB sponsored program shall be required to meet initial\nauthorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy\n-AND-\n(1) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nD. Non-radiographic Axia",
    "rcept), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nD. Non-radiographic Axial Spondyloarthritis\n1. Initial Authorization\na. Bimzelx will be approved based on the following criteria:\n(1) Diagnosis of active non-radiographic axial spondyloarthritis\n-AND-\n(2) One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date,\nand duration of trials)\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of non-radiographic axial spondyloarthritis as\n© 2025 UnitedHealthcare Services, Inc.\n7\ndocumented by claims history or submission of medical records (Document\ndrug, date, and duration of therapy) [e.g. Cimzia (certolizumab), Cosentyx\n(secukinumab), Rinvoq (upadacitinib)].\n-AND-\n(3) One of the following:\n(a) History of failure, contraindication, or intolerance to two of the following\npreferred products (document drug, date, and duration of trial):\ni. Cimzia (certolizumab)\nii. Cosentyx (secukinumab)\niii. Rinvoq (upadacitinib)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Bimzelx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a UCB sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a\nfree supply of medication) as a means to establish as a current user of\nBimzelx*\n-AND-\n(4) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Cosentyx\n(secukinumab), Simponi (golimumab), Orencia (abatacept), adalimu",
    " not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Cosentyx\n(secukinumab), Simponi (golimumab), Orencia (abatacept), adalimumab,\nXeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(5) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a UCB sponsored program shall be required to meet initial\nauthorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n8\na. Bimzelx will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy\n-AND-\n(1) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nE. Hidradenitis Suppurativa (HS)\n1. Initial Authorization\na. Bimzelx will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe hidradenitis suppurativa (i.e., Hurley Stage\nII or III)\n-AND-\n(2) One of the following:\n(a) Both of the following:\ni. History of failure to at least one oral antibiotic (e.g., doxycycline,\nclindamycin, rifampin) at maximally indicated doses, unless\ncontraindicated or clinically significant adverse effects are\nexperienced (document drug, date, and duration of trial)\n-AND-\nii. History of failure, contraindication, or intolerance to both of the\nfollowing preferred products (document drug, date, and duration of\ntrial):\n• One of the preferred adalimumab productsc\n• Cosentyx (secukinumab)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Bimzel",
    " preferred products (document drug, date, and duration of\ntrial):\n• One of the preferred adalimumab productsc\n• Cosentyx (secukinumab)\n-OR-\n(b) Both of the following:\ni. Patient is currently on Bimzelx therapy as documented by claims history\nor submission of medical records (Document date and duration of\ntherapy):\n© 2025 UnitedHealthcare Services, Inc.\n9\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a UCB sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a\nfree supply of medication) as a means to establish as a current user of\nBimzelx*\n-AND-\n(3) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx\n(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept),\nSimponi (golimumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from a UCB sponsored program shall be required to meet initial\nauthorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Bimzelx will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Bimzelx therapy.\n-AND-\n(2) Patient is not receiving Bimzelx in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Cosentyx\n(secukinumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia\n(abatacept), Simponi (golimumab), Rinvoq (upadacitinib), Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverag",
    "Xeljanz\n(tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\nc For a list of preferred products please reference drug coverage tools.\n© 2025 UnitedHealthcare Services, Inc.\n10\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Bimzelx [package insert]. Smyrna, GA: UCB, Inc.; November 2024\n2. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update\n2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol\n2015;29:2277-94.\n3. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management\nand treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.\nProgram Prior Authorization/Medical Necessity - Bimzelx (bimekizumab-bkzx)\nChange Control\n4/2024 New program\n6/2024 Added requirement for medical record submission for all authorization\ncriteria. Updated trial/failure criteria for Cosentyx. Removed\nreauthorization criteria.\n10/2024 Updated step requirement noting Adalimumab-adaz (unbranded\nHyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab\nproducts with no change to clinical intent. Removed preferred\nadalimumab footnote. Added Sotyktu as step therapy agent for PsO.\nChanged number of step requirement to two and added continutation of\ncare if already on Bimzelx. Removed notation of exclusion. Added\ncoverage criteria for PsA, AS, and nr-axSpA",
    "therapy agent for PsO.\nChanged number of step requirement to two and added continutation of\ncare if already on Bimzelx. Removed notation of exclusion. Added\ncoverage criteria for PsA, AS, and nr-axSpA. Updated background and\nreference.\n1/2025 Added criteria for hidradenitis suppurativa. Updated background and\nreference.\n4/2025 Removed examples for adalimumab in step therapy. Changed Stelara\nstep therapy to “One of the preferred ustekinumab productsc”. Changed\nStelara example to Ustekinumab. Added the footnote “For a list of\npreferred products please reference drug coverage tools.”\n© 2025 UnitedHealthcare Services, Inc.\n11"
  ]
}